| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.0091 | 0.8 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | selumetinib:JQ-1 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | -0.013 | 0.8 |